Treating depression in children and adolescents: What options now?

CNS Drugs

Volumn 20, Issue 1, 2006, Pages 1-13

  Varley, Christopher K ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

CLINICAL TRIAL; DEPRESSION; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; NEW ZEALAND; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; UNITED KINGDOM; UNITED STATES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; COMBINED MODALITY THERAPY; DEPRESSION; HUMANS; PSYCHOTHERAPY;

EID: 30344451995     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620010-00001     Document Type: Review

References (58)

1. Birmaher B, Ryan ND, Brent D, et al. Child and adolescent depression: a review of the past ten years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35: 1427-39
2. Fleming JE, Offord DR. Epidemiology of childhood depressive disorders: a critical review. J Am Acad Child Adolesc Psychiatry 1990; 29: 571-80
3. Garrison CZ, Addy CLK, Jackson KL, et al. Major depressive disorder and dysthymia in young adolescents. Am J Epidemiol 1992; 135: 792-802
4. Kashani JH, Beck NC, Hoeper EW, et al. Psychiatric disorders in a community sample of adolescents. Am J Psychiatry 1987; 144: 584-9
5. Kashani JH, Carlson GA, Beck NC, et al. Depression, depressive symptoms, and depressed mood among a community sample of adolescents. Am J Psychiatry 1987; 144: 931-4
6. Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety 1998; 7: 3-14
7. Lewinsohn PM, Hops H, Roberts RE, et al. Adolescent psychopathology I: prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 1993; 103: 133-44
8. Lewinsohn PM, Clarke GN, Seeley JR, et al. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 1994; 33: 809-18
9. Bae JS, MacLean MG, GA Marlatt, et al. Linking etiology and treatment for adolescent substance abuse: toward a better match. In: Jessor R, editor. New perspectives on adolescent risk behavior. New York: Cambridge University Press, 1998: 182-211
10. Gjerde PF, Westenberg PM. Dysphoric adolescents as young adults: a prospective study of the psychological sequelae of depressed mood in adolescence. J Res Adolesc 1998; 8 (3): 377-402
11. Hammen C. Depression. Hove, England: Psychology Press/Erlbaum, 1997
12. Emslie GJ, Rush AJ, Weinberg WA, et al. A double blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-7
13. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205-15
14. Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004; 292: 807-20
15. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depressive disorder: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762-72
16. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290: 1033-41
17. Wagner KD, Robb AS, Findling RL, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161 (6): 1079-83
18. Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003; 42: 22-9
19. Emslie GJ, Findling RL, Rynn MA, et al. Efficacy and safety of nefazodone in the treatment of adolescents with major depressive disorder [abstract]. 42nd Annual Meeting of NCDEU; 2002; Orlando (FL)
20. Milin RP, Simeon J, Spenst WP. Double-blind study of paroxetine in adolescents with unipolar major depression [abstract NR67 104-105 plus poster]. 46th Annual American Academy of Child and Adolescent Psychiatry Meeting; 1999 Oct 19-21; Chicago (IL)
21. Mandoki MW, Tapia MR, Tapia MA, et al. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 1997; 33: 149-54
22. Wagner DW, Jonas J, Bose A. Controlled trial of escitalopram in the treatment of pediatric depression. Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2004 Oct 19-24; Washington, DC
23. Duff G. Safety and efficacy of the SSRI class in the treatment of paediatric major depressive disorder. Expert Working Group on Safety of Medicines. 2003 [online]. Available from URL: http://www.mhra.gov.uk. [Accessed 2005 Mar 28]
24. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished date. Lancet 2004; 363: 1341-5
25. GlaxoSmithKline. Paroxetine and Pediatric Patients [online]. Available from URL: http://www.gsk.com/media/paroxetine.htm [Accessed 2005 Mar 28]
26. US Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications. FDA Public Health Advisory, 2004 October 15 [online]. Available from URL: http://www.fda.gov/cder/drug/ antidepressants/SSRIPHA200410.htm [Accessed 2005 Mar 28]
27. Bemporad JR. Psychodynamic treatment of depressed adolescents. J Clin Psychiatry 1988 Sep; 49: 26-31
28. Fine S, Forth A, Gilbert M, et al. Group therapy for adolescent depressive disorder: a comparison of social skills and therapeutic support. J Am Acad Child Adolesc Psychiatry 1991; 30: 79-85
29. Curry JF. Specific psychotherapies for childhood and adolescent depression. Biol Psychiatry 2001; 49 (12): 1091-100
30. Lewinsohn PM, Clarke GN. Psychosocial treatments for adolescent depression. Clin Psychol Rev 1999; 19 (3): 329-42
31. Marcotte D. Treating depression in adolescence: a review of the effectiveness of cognitive-behavioral treatments. J Youth Adolesc 1997; 26 (3): 273-83
32. Reinecke MA, Ryan NE, DuBois DL. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 1998; 37: 26-34
33. Brent DA, Holder D, Birmaher B, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 1997; 54: 877-85
34. Clarke GN, Rohde P, Lewinsohn PM, et al. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry 1999; 38: 272-9
35. Wood A, Harrington R, Moore A. Controlled trial of a brief cognitive-behavioral intervention in adolescent patients with depressive disorders. J Child Psychol Psychiatry 1996; 37 (6): 737-46
36. Brent DA, Kolko D, Birmaher B, et al. Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry 1998; 37: 906-14
37. Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 2000; 57: 29-36
38. Mufson L, Moreau D, Weissman MM, et al. Modification of interpersonal psychotherapy with depressed adolescents (IPT-A): phase I and II studies. J Am Acad Child Adolesc Psychiatry 1994; 33: 695-705
39. Mufson L, Dorta KP, Wickramarante P, et al. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004; 61: 577-84
40. Mufson L, Weissman MM, Moreau D, et al. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 1999; 56: 573-9
41. Mufson L, Fairbanks J. Interpersonal psychotherapy for depressed adolescents: a one-year naturalistic follow-up study. J Am Acad Child Adolesc Psychiatry 1996; 35: 1145-55
42. Duff G. Safety of Seroxat (paroxetine) in children and adolescents under 18 years: contraindication in the treatment of depressive illness. United Kingdom's Department of Health's Chairman of Committee of Safety of Medicine's message on paroxetine. 2003 [online]. Available from URL: http://www.mhra.gov.uk [Accessed 2005 Mar 28]
43. US Food and Drug Administration. FDA statement regarding the anti-depressant Paxil for pediatric population. FDA Talking Paper, June 19, 2003 [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/2003/ ANS01230.html. [Accessed 2005 Mar 28]
44. American Psychiatric Association, American Academy of Child and Adolescent Psychiatry. PhysiciansMedGuide: the use of medication in treating childhood and adolescent depression. Information for physicians. 2005 Feb 1 [online]. Available from URL: http://www.parentsmedguide.org/parentsmedgcents. uide.htm [Accessed 2005 Mar 28]
45. New Zealand Medicines and Medical Devices Safety Authority. The use of SSRI and antidepressants in children and adolescents. March 22, 2004 [online]. Available from URL: http://www.medsafe.govt.nz [Accessed 2005 Mar 28]
46. Health Canada. Health Canada advises Canadians of stronger warnings for SSRIs and other newer antide-depressants. 2004 Jun 3 [online]. Available from URL: http://www.he-sc/gc/ca/English/protection/warnings/2004/2004_31.htm [Accessed 2005 Mar 28]
47. The Adverse Drug Reactions Advisory Committee. Use of SSRI antidepressants in children and adolescents: 2004 Oct 15 [online]. Available from URL: http://www.tga.gov.au/adr/adrac_ssri.htm [Accessed 2005 Mar 28]
48. Jureidini JN, Head I, Doecke CJ, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879-83
49. Zito JM, Derivan AT, Greenhill L. Making research data available: an ethical imperative demonstrated by the SSRI debacle. J Am Acad Child Adolesc Psychiatry 2004; 43 (5): 512-4
50. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996; 35: 705-15
51. Weissman MM, Wolk S, Wickramaratne P, et al. Children with prepubertal-onset major depressive disorder and anxiety grown up. Arch Gen Psychiatry 1999; 56: 794-801
52. Varley CK. Psychopharmacological treatment of major depressive disorder in children and adolescents. JAMA 2003; 90 (8): 1091-3
53. Olfson M, Shaffer D, Marcus S. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978-82
54. Delate T, Gelenberg AJ, Simmons VA, et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv 2004; 55 (4): 387-91
55. Zito JM, Safer DJ, dos Reis S. Rising prevalence of antidepressant treatment for US children and adolescents. Pediatrics 2002; 109: 712-27
56. Hughes CL, Emslie GJ, Crismon ML, et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1442-54
57. Varley CK. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications. Paediatr Drugs 2001; 3 (8): 613-27
58. Kratochvil CJ, Wagner KD, Emslie G, et al. Pharmacological management of treatment-resistant pediatric depression. J Am Acad Child Adoles Psych 2005; 44: 198-200